| Autor: |
Mary E.D. Flowers, Stephanie J. Lee, Stefanie Sarantopoulos, Paul J. Martin, Howard M. Shulman, David B. Miklos, Barry E. Storer, Yoshihiro Inamoto, Teresa S. Hyun, Michael Green, William A. Wood, Sebastian A. Mayer, Madan H. Jagasia, George L. Chen, Jeanne Palmer, Nandita Khera, Samantha Jaglowski, Xiaoyu Chai, Iskra Pusic, Joseph Pidala, Sally Arai |
| Rok vydání: |
2023 |
| Popis: |
Supplemental Table. Grade 3-5 adverse events possibly, probably or definitely attributed to imatinib or rituximab Supplemental Figure 1. Vienna Skin Score (VSS) (1) Supplemental Figure 2. Photograph Range of Motion Scale - Modified from (2) Supplemental Figure 3. Total numbers of B cells (CD19+ CD3- lymphocytes) was calculated in patients analyzed in Figure 3 who had available absolute lymphocyte counts. Supplemental Figure 4. BAFF levels at enrollment across treatment groups. Plasma soluble BAFF levels were determined in patients who later either experienced treatment success or did not respond to imatinib or rituximab. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
